Results 261 to 270 of about 87,574 (284)
Some of the next articles are maybe not open access.
Subcutaneous immunoglobulin treatment and thromboembolic risk
Annals of Allergy, Asthma & Immunology, 2018n.a.
Vacchiano, Veria +4 more
openaire +3 more sources
Immunoglobulin Replacement Therapy by Slow Subcutaneous Infusion
Annals of Internal Medicine, 1980Excerpt Alcohol fractionated immune serum globulin and fresh frozen plasma are the only generally available preparations used for replacement therapy in patients with antibody deficiency syndromes....
M, Berger, T R, Cupps, A S, Fauci
openaire +2 more sources
Subcutaneous Immunoglobulin in Oncology Clinical Practice
Clinical Journal of Oncology Nursing, 2016The administration of gammaglobulin as replacement therapy to boost immune function in patients with immunodeficiency secondary to malignancy is traditionally given in the IV formulation. A pilot program at a large Canadian cancer center led by an advanced practice nurse (APN) demonstrated that transitioning patients to home-based, self-administered ...
openaire +2 more sources
Subcutaneous immunoglobulin therapy for multifocal motor neuropathy
Journal of the Peripheral Nervous System, 2009Abstract The objective of this study was to investigate whether subcutaneous immunoglobulin (SCIg) treatment is feasible and safe in maintaining muscle strength of patients with multifocal motor neuropathy (MMN). Patients fulfilling the EFNS/PNS criteria for definite MMN treated with intravenous immunoglobulin (IVIg) were switched to ...
Eftimov, Filip +4 more
openaire +2 more sources
Subcutaneous immunoglobulin replacement in primary immunodeficiencies
Clinical Immunology, 2004The use of small portable pumps for subcutaneous infusion of IgG in patients with primary immunodeficiencies was introduced more than 20 years ago. In the US, i.v.i.g. became more popular, but in other countries, many patients use the subcutaneous route.
openaire +2 more sources
Why I Use Subcutaneous Immunoglobulin (SCIG)
Journal of Clinical Immunology, 2012Immunoglobulin (IgG) replacement is a life-saving treatment for individuals with primary immunodeficiency disease (PIDD). Today, there are many options for IgG replacement, and the choice is an individual one based on many factors. My preference for most patients is the subcutaneous (SCIG) route. It offers many advantages not offered by the intravenous
openaire +2 more sources
Subcutaneous immunoglobulin for patients with antibody deficiency
British Journal of Hospital Medicine, 2007This article provides an overview on the management of primary immunodeficiency, and discusses the pharmacokinetics of subcutaneous and intravenous immunoglobulin and the relationship between blood levels and therapeutic effects in both treatments. The article will further highlight both treatments' efficacy in preventing infections and the risk of ...
Matthew, Helbert, Alex, Farragher
openaire +2 more sources
Intravenous and subcutaneous immunoglobulin G replacement therapy
Allergy and Asthma Proceedings, 2016Human polyclonal immunoglobulin G (IgG) for therapeutic use has been available for decades. This drug was developed for treatment of antibody deficiency (replacement therapy), although its use has expanded into many anti-inflammatory and immunomodulatory applications in recent years. This review focuses on IgG prescribing for replacement therapy.
openaire +2 more sources
Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia
Clinical Immunology, 2016In this study, we compared intravenous immunoglobulins (IVIG) and subcutaneous immunoglobulins (SCIG) in terms of serum IgG concentration and incidence of infections in patients with hypogammaglobulinemia secondary to chemo-immunotherapy regimens including the anti-CD20 monoclonal antibody rituximab.
SPADARO, GIUSEPPE +4 more
openaire +2 more sources
Subcutaneous immunoglobulin therapy home.
Nursing times, 2014Subcutaneous immunoglobulin (SClg) replacement therapy is a new clinical service development in adult respiratory care undertaken at the Royal Brompton and Harefield Foundation Trust. SCIg therapy reduces appropriate patients' susceptibility to recurrent acute and chronic respiratory infections. Patients with specific chronic respiratory conditions and
openaire +1 more source